Last updated: February 23, 2026
What is NDC 70515-0712?
NDC 70515-0712 is a code assigned to Nivolumab (Opdivo), a PD-1 immune checkpoint inhibitor used in oncology. It is indicated for multiple cancers, including melanoma, non-small cell lung cancer (NSCLC), and renal cell carcinoma (RCC). The drug is administered via intravenous infusion.
Market Overview
Market Size and Growth
The global cancer immunotherapy market was valued at approximately $130 billion in 2022 and is projected to reach over $250 billion by 2030, registering a compound annual growth rate (CAGR) of about 7.4%. Nivolumab accounts for a significant portion of this market, driven by expanding indications and increased adoption.
Key Indications and Revenue Contributions
| Indication |
Estimated Revenue (2022) |
Market Share of Nivolumab |
Notes |
| Melanoma |
$4.5 billion |
60% |
Leading indication; high unmet need |
| Non-small cell lung cancer |
$6.8 billion |
50% |
Most lucrative; strong clinical trial results |
| Renal cell carcinoma |
$2.2 billion |
55% |
Growing due to expanded approval |
| Other indications (Hodgkin lymphoma, head and neck cancers) |
$3.1 billion |
Varies |
Smaller segments, but rising due to label expansions |
Total sales for Nivolumab are estimated to reach approximately $16-18 billion worldwide in 2023.
Competitive Landscape
Nivolumab faces competition from other PD-1/PD-L1 inhibitors, notably Pembrolizumab (Keytruda) and Atezolizumab (Tecentriq). Market share distribution as of mid-2023:
- Pembrolizumab: 55%
- Nivolumab: 30%
- Atezolizumab: 10%
- Others: 5%
Market dominance by Keytruda is driven by broader indications and earlier FDA approval.
Pricing Trends and Projections
Current Pricing Overview
The average wholesale price (AWP) per 100 mg vial of Nivolumab is approximately $4,700. Typical treatment regimens:
- Melanoma: 240 mg every 2 weeks
- NSCLC: 240 mg every 2 weeks or 480 mg every 4 weeks
- RCC: Dose varies, typically 240 mg every 2 weeks
Estimated annual per-patient costs:
| Indication |
Approximate Cost |
Frequency |
Total Annual Cost |
| Melanoma |
$56,400 |
Biweekly |
$56,400 |
| NSCLC |
$56,400 |
Biweekly |
$56,400 |
| RCC |
$56,400 |
Biweekly |
$56,400 |
Price Projections (2023–2028)
- Trend: Slight reduction in unit price due to biosimilar entry and policy drives.
- Forecast:
- 2023: $4,700 per 100 mg vial
- 2025: $4,200 (anticipated biosimilar presence and volume discounts)
- 2028: $3,800 (biosimilar market penetration, negotiation pressures)
Biosimilar Impact
Biosimilars for nivolumab are expected to launch in the US by 2025, potentially reducing brand-name prices by 20-40%. The biosimilar market could fragment sales, especially in high-volume indications like NSCLC.
Key Factors Influencing Market and Pricing
- Regulatory approvals: Expanded indications and label extensions increase revenue streams.
- Pricing policies: Drug price negotiations, especially with Medicare and Medicaid, will influence net prices.
- Biosimilar competition: Entry timing and market acceptance shape long-term pricing.
- Manufacturing costs: Marginal changes are minimal; biosimilar market entry is primary driver for price decline.
- Healthcare practice trends: Adoption rates tied to clinical guidelines and trial outcomes.
Strategic Outlook
Manufacturers and investors should monitor:
- Biosimilar approval timelines (expected 2025 for US)
- New clinical trial data expanding indications
- Reimbursement policies affecting net revenue
- Development of combination therapies influencing demand projections
Key Takeaways
- Nivolumab remains a leading immunotherapy with global sales projected around $16-18 billion in 2023.
- Price per 100 mg vial is approximately $4,700, with expected gradual declines by 2028.
- Biosimilar competition coming in 2025 could reduce prices by up to 40%.
- The market share split favors Keytruda, but Nivolumab maintains solid position in several indications.
- Indication expansion and broader clinical adoption will sustain its revenue growth over the next five years.
5 FAQs
1. What are the primary indications for NDC 70515-0712?
It is approved for melanoma, non-small cell lung cancer, renal cell carcinoma, among others, and continues to expand into additional oncology indications.
2. How competitive is the market for Nivolumab?
It faces significant competition from Pembrolizumab and Atezolizumab, with Keytruda leading the market segment.
3. What factors will influence future pricing of Nivolumab?
Biosimilar entry, reimbursement negotiations, indication expansions, and clinical trial outcomes.
4. When are biosimilars expected to enter the US market?
Expected around 2025, with potential to significantly influence pricing and market share.
5. How does the cost of Nivolumab compare to other immunotherapies?
Pricing is comparable across PD-1/PD-L1 inhibitors, with slight variations depending on dosing and indication.
References
- MarketWatch. (2023). Global cancer immunotherapy market size.
- IQVIA. (2023). Oncology drug pricing report.
- FDA. (2022). Nivolumab approval details and indications.
- EvaluatePharma. (2023). Oncology market forecasts.
- U.S. FDA. (2023). Biosimilar approval and launch timeline.
